Context Therapeutics (CNTX) Competitors $0.66 +0.02 (+3.67%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$0.65 0.00 (-0.46%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTX vs. IMAB, PRQR, SOPH, SCPH, MNPR, YMAB, CRGX, GNFT, PROK, and DRUGShould you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include I-Mab (IMAB), ProQR Therapeutics (PRQR), SOPHiA GENETICS (SOPH), scPharmaceuticals (SCPH), Monopar Therapeutics (MNPR), Y-mAbs Therapeutics (YMAB), CARGO Therapeutics (CRGX), GENFIT (GNFT), ProKidney (PROK), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. Context Therapeutics vs. Its Competitors I-Mab ProQR Therapeutics SOPHiA GENETICS scPharmaceuticals Monopar Therapeutics Y-mAbs Therapeutics CARGO Therapeutics GENFIT ProKidney Bright Minds Biosciences I-Mab (NASDAQ:IMAB) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations. Which has preferable valuation & earnings, IMAB or CNTX? I-Mab has higher revenue and earnings than Context Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioI-Mab$3.89M46.81-$22.23MN/AN/AContext TherapeuticsN/AN/A-$26.73M-$0.31-2.11 Which has more risk and volatility, IMAB or CNTX? I-Mab has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500. Do institutionals & insiders have more ownership in IMAB or CNTX? 38.4% of I-Mab shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 2.8% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer IMAB or CNTX? I-Mab presently has a consensus target price of $6.00, suggesting a potential upside of 169.06%. Context Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 739.69%. Given Context Therapeutics' higher possible upside, analysts plainly believe Context Therapeutics is more favorable than I-Mab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score I-Mab 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media prefer IMAB or CNTX? In the previous week, I-Mab had 3 more articles in the media than Context Therapeutics. MarketBeat recorded 4 mentions for I-Mab and 1 mentions for Context Therapeutics. I-Mab's average media sentiment score of 0.22 beat Context Therapeutics' score of 0.00 indicating that I-Mab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is IMAB or CNTX more profitable? I-Mab's return on equity of -19.81% beat Context Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets I-MabN/A -19.81% -18.63% Context Therapeutics N/A -29.78%-29.08% SummaryI-Mab beats Context Therapeutics on 9 of the 12 factors compared between the two stocks. Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTX vs. The Competition Export to ExcelMetricContext TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.76M$2.41B$5.49B$9.02BDividend YieldN/A1.77%5.38%4.10%P/E Ratio-2.118.9827.4720.28Price / SalesN/A669.86408.86121.46Price / CashN/A157.0736.6357.47Price / Book0.524.638.095.68Net Income-$26.73M$31.34M$3.17B$248.96M7 Day Performance-0.79%3.25%2.81%3.30%1 Month Performance13.85%6.80%3.67%5.20%1 Year Performance-63.41%1.89%35.41%21.37% Context Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTXContext Therapeutics3.3695 of 5 stars$0.66+3.7%$5.50+739.7%-63.4%$58.76MN/A-2.117IMABI-Mab3.1049 of 5 stars$2.46-1.6%$5.50+123.6%+48.7%$204.15M$3.89M0.00380PRQRProQR Therapeutics2.1894 of 5 stars$1.95+1.0%$8.00+310.3%+30.7%$203.06M$20.46M-5.57180News CoverageSOPHSOPHiA GENETICS2.836 of 5 stars$3.05+0.3%$6.80+123.0%-35.8%$202.73M$65.17M-3.05520SCPHscPharmaceuticals4.1624 of 5 stars$3.83-0.3%$14.00+265.5%-6.6%$202.72M$36.33M-2.0130MNPRMonopar Therapeutics3.2259 of 5 stars$31.83-3.1%$56.50+77.5%+919.9%$200.95MN/A-9.1510YMABY-mAbs Therapeutics2.6069 of 5 stars$4.72+7.0%$15.60+230.5%-62.2%$199.70M$87.68M-7.38150News CoverageCRGXCARGO Therapeutics1.6844 of 5 stars$4.13-3.3%$15.00+263.2%-70.9%$196.89MN/A-0.89116GNFTGENFIT2.0207 of 5 stars$3.81-3.1%$13.00+241.2%-4.0%$196.49M$76.77M0.00120Gap DownPROKProKidney1.8465 of 5 stars$0.61-8.2%$4.50+642.6%-70.4%$193.21M$80K-1.013News CoverageGap UpHigh Trading VolumeDRUGBright Minds Biosciences3.18 of 5 stars$27.09-0.8%$83.25+207.3%+2,544.9%$192.37MN/A-75.25N/ANews CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies IMAB Alternatives PRQR Alternatives SOPH Alternatives SCPH Alternatives MNPR Alternatives YMAB Alternatives CRGX Alternatives GNFT Alternatives PROK Alternatives DRUG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing t...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTX Stock Alerts